87 related articles for article (PubMed ID: 38702828)
1. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Pothuri B; Han S; Chase DM; Heitz F; Burger RA; Gaba L; Van Le L; Guerra E; Bender D; Korach J; Cloven N; Churruca C; Follana P; DiSilvestro P; Baurain JF; Jardon K; Pisano C; Peen U; Mäenpää J; Gupta D; Bacqué E; Li Y; Compton N; Antonova J; Monk BJ; González-Martín A
Gynecol Oncol; 2024 May; 184():168-177. PubMed ID: 38325276
[TBL] [Abstract][Full Text] [Related]
3. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Musacchio L; Palluzzi E; Di Napoli M; Lauria R; Ferrandina G; Angioli R; Bergamini A; Corrado G; Perniola G; Cassani C; Savarese A; Gori S; Greco F; De Angelis C; Zafarana E; Giannarelli D; Cinieri S; Mosconi AM; Raspagliesi F; Pignata S; Scambia G; Lorusso D
Gynecol Oncol; 2024 May; 184():24-30. PubMed ID: 38277918
[TBL] [Abstract][Full Text] [Related]
4. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Falchook G; Patnaik A; Richardson DL; Harvey RD; Sharma MR; Hafez N; Hamilton E; Piha-Paul SA; Barve M; Wise-Draper T; Patel MR; Dowlati A; Pascuzzo J; Tang SC; Faltermeier C; Malinowska IA; Shtessel L; Striha A; Potocka E
Clin Ther; 2024 Mar; 46(3):228-238. PubMed ID: 38423866
[TBL] [Abstract][Full Text] [Related]
5. Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer.
Uekusa R; Yokoi A; Watanabe E; Yoshida K; Yoshihara M; Tamauchi S; Shimizu Y; Ikeda Y; Yoshikawa N; Niimi K; Suzuki S; Kajiyama H
Sci Rep; 2024 Jun; 14(1):12595. PubMed ID: 38824213
[TBL] [Abstract][Full Text] [Related]
6. Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.
Makar AP; Tropé CG; Tummers P; Denys H; Vandecasteele K
Oncologist; 2016 Jun; 21(6):745-54. PubMed ID: 27009938
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DG; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1239-1242. PubMed ID: 32591370
[TBL] [Abstract][Full Text] [Related]
8. MIRRORS: a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer.
Uwins C; Assalaarachchi H; Bennett K; Read J; Tailor A; Crawshaw J; Chatterjee J; Ellis P; Skene SS; Michael A; Butler-Manuel S
Int J Gynecol Cancer; 2024 Jun; 34(6):886-897. PubMed ID: 38561194
[TBL] [Abstract][Full Text] [Related]
9. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
Holloway RW; Mendivil AA; Kendrick JE; Abaid LN; Brown JV; LeBlanc J; McKenzie ND; Mori KM; Ahmad S
JAMA Oncol; 2023 Jul; 9(7):903-908. PubMed ID: 37227734
[TBL] [Abstract][Full Text] [Related]
10. Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT).
Kobayashi Y; Shimada M; Tamate M; Cho HW; Zhu J; Chou HH; Kajiyama H; Okamoto A; Aoki D; Kang S; Lee JW; Kim JW; Kim JH; Lin Z; Liu J; Wu X; Lai HC; Chang TC; Lai CH; Kim YM; Enomoto T
J Gynecol Oncol; 2024 May; 35(3):e87. PubMed ID: 38606827
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Future Oncol; 2024 Mar; ():1-14. PubMed ID: 38501262
[TBL] [Abstract][Full Text] [Related]
12. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
du Bois A; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J
Cancer; 2009 Mar; 115(6):1234-44. PubMed ID: 19189349
[TBL] [Abstract][Full Text] [Related]
13. First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.
Wu X; Liu J; An R; Yin R; Zhang Y; Zhou H; He A; Wang L; Zhang J; Liu Z; Duan W; Zhu J; Lou G; Chen G; Cheng Y; Xue F; Nick S; Wang H; Li D
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38872480
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Valabrega G; Pothuri B; Oaknin A; Graybill WS; Sánchez AB; McCormick C; Baurain JF; Tinker AV; Denys H; O'Cearbhaill RE; Hietanen S; Moore RG; Knudsen AØ; de La Motte Rouge T; Heitz F; Levy T; York W; Gupta D; Monk BJ; González-Martín A
Gynecol Oncol; 2024 Jun; 187():128-138. PubMed ID: 38833992
[TBL] [Abstract][Full Text] [Related]
15. Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients.
Bruno M; Apostol AI; Boccia SM; Sassu CM; Lardino S; Culcasi C; Lorusso D; Scambia G; Fagotti A; Marchetti C
Int J Gynecol Cancer; 2024 Jun; ():. PubMed ID: 38858105
[TBL] [Abstract][Full Text] [Related]
16. The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy.
Hopkins L; Carey M; Brown L; McCrea S; Milne M; Tokaryk D; Stacey D
Curr Oncol; 2024 Mar; 31(3):1416-1425. PubMed ID: 38534940
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of niraparib for
Kawamoto Y; Morizane C; Komatsu Y; Kondo S; Ueno M; Kobayashi S; Furukawa M; Lee L; Satoh T; Sakai D; Ikeda M; Imaoka H; Miura A; Hatanaka Y; Yokota I; Nakamura Y; Yoshino T
Future Oncol; 2024 Apr; ():1-7. PubMed ID: 38629456
[TBL] [Abstract][Full Text] [Related]
18. Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy.
Chase D; Perhanidis J; Gupta D; Kalilani L; Golembesky A; González-Martín A
JCO Clin Cancer Inform; 2023 Jun; 7():e2200189. PubMed ID: 37294913
[TBL] [Abstract][Full Text] [Related]
19. Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China.
Yu J; Liu H; Wu Y
BMJ Open; 2024 May; 14(5):e081090. PubMed ID: 38806431
[TBL] [Abstract][Full Text] [Related]
20. Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.
Suh DH; Kim M; Kim K; Kim HJ; Lee KH; Kim JW
J Gynecol Oncol; 2017 May; 28(3):e45. PubMed ID: 28382802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
